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Abstract
Background: Coronary heart disease (CHD) is a major cause of morbidity and mortality in
Australia and it is recommended that all persons with unstable angina (UA) or myocardial infarction
(MI) participate in secondary prevention as offered in cardiac rehabilitation (CR) programs.
However, the majority of patients do not access standard CR and have higher baseline coronary
risk and poorer knowledge of CHD than those persons due to commence CR. The objective of
this study is to investigate whether a modular guided self-choice approach to secondary prevention
improves coronary risk profile and knowledge in patients who do not access standard CR.
Methods/Design: This randomised controlled trial with one year follow-up will be conducted at
a tertiary referral hospital. Participants eligible for but not accessing standard CR will be randomly
allocated to either a modular or conventional care group. Modular care will involve participation
in individualised modules that involve choice, goal-setting and coaching. Conventional care will
involve ongoing heart disease management as directed by the participant's doctors. Both modular
and conventional groups will be compared with a contemporary reference group of patients
attending CR. Outcomes include measured modifiable risk factors, relative heart disease risk and
knowledge of risk factors.
Discussion: We present the rationale and design of a randomised controlled trial testing a
modular approachfor the secondary prevention of coronary heart disease following acute coronary
syndrome.
Background
Coronary heart disease (CHD) is a major cause of morbid-
ity and mortality in Australia and is associated with signif-
icant cost [1]. Australian guidelines recommend all
persons with unstable angina (UA) or myocardial infarc-
tion (MI) participate in secondary prevention [2] incorpo-
rating risk factor management. Risk factor modification
including lifestyle change and the use of vasoprotective
medications is an effective means extending overall sur-
vival, reducing non-fatal cardiovascular events, decreasing
the need for coronary revascularisation, enhancing quality
of life (QOL) [3] and improving coronary endothelial
function [4,5]. Importantly, CHD is a chronic illness that
is best managed when positive health behaviors become
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integrated into long-term lifestyle habits therefore, strate-
gies are needed to motivate and support patients to con-
sistently follow multidimensional treatment regimens.
Cardiac rehabilitation is a widely recognised form of sec-
ondary prevention [6], but participation rates are low
(10–30%) [7,8] because of transport difficulties, work
and social commitments and a lack of perceived need [9].
Despite clear short-term benefits for attendees, large
groups of patients are not benefiting, which presents an
opportunity and challenge to improve CHD care [10].
Importantly, there are limited studies reporting the risk
profile of patients not accessing formal rehabilitation.
One observational Australian study demonstrated that
non-participants were at higher risk of recurrent events
than patients attending rehabilitation [11]. Similarly,
functional impairment has been shown to be the strong-
est predictor of non-participation in cardiac rehabilitation
after coronary artery bypass graft surgery [10]. These find-
ings are of major concern because the patients who stand
to benefit the most from secondary prevention are the
people least likely to participate.
One pilot study has clinically investigated secondary pre-
vention of CHD using a 'modular' approach and demon-
strated enhanced completion rates and cost effectiveness
[12]. For the study, a metropolitan cardiac rehabilitation
program was offered as individual components, or mod-
ules, based on patient need rather than an all-or-nothing
exercise-based approach. The pilot study was an impor-
tant step from standard cardiac rehabilitation however,
the modules were still conducted in a group environment
and were predominantly based on education without for-
mal goal setting and follow-up. Results of the pilot study
suggest it is likely that the development and evaluation of
more detailed unique risk factor modules may enhance
long-term outcomes.
The inclusion of multidimensional behavior modification
techniques such as goal setting and offering a wide range
of individually tailored services may enhance compliance
with long-term risk factor interventions [13]. For chronic
disease, it is important to conceptualise change in a posi-
tive light to reduce anxiety about the disease rather than
focusing on negative aspects of making a change [14]. Set-
ting of mutually-agreed, realistic and readily identifiable
goals with clear time frames helps enhance active patient
orientation and motivation and therefore facilitates
behavior change [14,15]. Further, the inclusion of a rating
of confidence for goal achievement may improve the
health professional's insight into a patient's intrinsic
motivation to change [14].
Facilitation of collaborative relationships, shared deci-
sion-making, offering choice and communication of
expectations in a supportive environment helps motivate
behavior change and therefore contributes to the disease
management process [15,16]. Formation of collaborative
relationships decreases patient anxiety and dissatisfaction
that is often related to uncertainty and lack of informa-
tion, explanation and feedback [17]. Studies have demon-
strated that encouraging patients to participate in
treatment decisions improves health status, QOL [18,19],
satisfaction, compliance and treatment outcomes [20].
More specifically, patients with a higher degree of active
orientation are more likely to comply with treatment rec-
ommendations for BP [16], diabetes and physical activity
[21]. Offering choice, in situations where there are several
management options based on individual preferences or
circumstances is a further method of enhancing active
patient orientation [22]. It is also suggested that options
offered as a menu of strategies are more successful because
it encourages each patient's task to be one of "choosing
rather than refuting" [14]. We have chosen the term
'guided self-choice' to describe this model which creates a
collaborative encounter, similar to the spirit of behavior
counseling [23].
The objective of this study is to investigate whether a mod-
ular guided self-choice approach to secondary prevention
improves coronary risk profile and knowledge in acute
coronary syndrome (ACS) patients who do not access
standard cardiac rehabilitation.
Methods/Design
Design
This randomised controlled trial with one year follow-up
will be conducted at a tertiary referral hospital in Sydney,
Australia. Participants not attending standard cardiac
rehabilitation will be randomly allocated to either a mod-
ular secondary prevention (experimental) or a conven-
tional care (control) group. A third contemporary group
of patients attending standard cardiac rehabilitation will
also be recruited (reference group). Ethical approval for
the study has been granted by both the Central Sydney
Area Health Service CRGH Zone and the University of
Sydney Human Research Ethics Committees. Written and
informed consent will be obtained from all participants
prior to commencement.
Independent variables are the identification of individual-
ised risk factor goals and participation in self chosen sec-
ondary prevention modules. The dependent variables are
assessment of cardiac risk factors, the achievement of risk
factor goals, unplanned hospital readmissions, quality of
life, relative cardiac risk and knowledge of risk factors. The
measurement and recording of experimental variables
will be conducted under blind conditions.BMC Cardiovascular Disorders 2006, 6:26 http://www.biomedcentral.com/1471-2261/6/26
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Study population
To establish a recruitment database, a list of all admis-
sions to a single metropolitan tertiary referral hospital in
Sydney Australia, with an ACS during a 10 month period,
was obtained using diagnostic related codes [24] for UA
(F72A, F72B), MI (F41A, F41B, F60A, F60B) and chest
pain (F74Z). For all admitted patients, the hospital medi-
cal records were reviewed to determine secondary preven-
tion eligibility. Reasons for ineligibility included
geography (living outside a 20 km radius of the hospital),
insufficient English language to provide informed con-
sent, congestive heart failure, the presence of a severe co-
morbidity (eg, end stage renal disease, Parkinson's dis-
ease, cancer) and death.
Inclusion criteria for the randomised conventional care
and modular groups were:
- No previous attendance at a formal cardiac rehabilita-
tion program including those who refused the initial invi-
tation to participate and those who failed to attend the
initial cardiac rehabilitation assessment.
- Diagnosis of ACS in the six months prior to recruitment.
- Ability to understand sufficient English to give written
and informed consent.
Inclusion criteria for non-randomised standard rehabilita-
tion group were:
- Commencing attendance at the CRGH cardiac rehabili-
tation program during the data collection period of the
study.
- Diagnosis of ACS in the six months prior to recruitment.
- Ability to understand sufficient English to give written
and informed consent.
Exclusion criteria were the same for all three groups in the
study and were:
- Clinical diagnosis of uncompensated, severe cardiac fail-
ure (Class IV).
- Uncontrolled arrhythmia or angina
- Severe or symptomatic aortic stenosis
- Persistent hypotension (SBP < 90 mmHg)
- Clinical diagnosis of a severe co-existing medical condi-
tion that would prevent participation (eg, dementia, a
rapidly deteriorating terminal illness or severe or active
rheumatoid arthritis)
Once the database of eligible patients is constructed, all
patients will be contacted by mail and telephone and
asked to volunteer for research investigating heart disease
risk factors. Recruitment mail-outs will be conducted in
batches of 30 to enable staggered recruitment over
approximately six months. Patients will be contacted
within two weeks of the mail-out to establish whether
they would be prepared to volunteer.
Group allocation
For the standard cardiac rehabilitation group, participants
will be consecutively recruited prior to commencement of
outpatient cardiac rehabilitation. Patients who are eligible
for but not participating in cardiac rehabilitation will be
randomly allocated to either their modular or conven-
tional care group immediately following completion of
the baseline assessment. Therefore, the researcher con-
ducting each baseline assessment will be blinded to group
allocation. Prior to study commencement, a computer-
generated allocation sequence will be constructed using
randomly permutated blocks [25]. An individual not
involved in the study recruitment, data collection or anal-
ysis will produce consecutively numbered sealed opaque
envelopes containing each participant's allocation. Fol-
lowing baseline assessment, the researcher will select the
next consecutively numbered envelope and open it to
reveal the allocated group. They will then notate the
unique patient identifier on the front on the participants
cover sheet. Therefore, group allocation will be concealed
from the researcher conducting baseline assessments.
Outcome measures
Assessments will be conducted in the hospital consulting
rooms or in the participant's home, if they are unable to
travel to the hospital. Demographic, subjective and objec-
tive information will be obtained during face-to-face
assessments at baseline, three and 12 months. Informa-
tion will include past history, nature of ACS, family his-
tory, age, medications and dose, presence of other
cardiovascular disease and the nature and date of any
revascularisation. In addition, contact details for each par-
ticipant, their general practitioner and their cardiologist
will be documented.
At three and 12 month follow-up, all baseline measures
will be repeated during face-to-face assessments by a
researcher blinded to group allocation. Additional col-
lected information will include – details of unplanned
hospital admissions, medications and doses along with
details of any health interventions undertaken by the par-
ticipant pertaining to their heart health, such as visits to
the GP and attendance at community programs. For par-BMC Cardiovascular Disorders 2006, 6:26 http://www.biomedcentral.com/1471-2261/6/26
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ticipants in the standard rehabilitation group, details of
participation in the cardiac rehabilitation program will
also be recorded such as duration and attendance at exer-
cise and education sessions.
Modifiable risk factors to be measured are serum choles-
terol, BP, smoking status, physical activity, overweight
and depression. Lipids and substrates will be measured on
a fasting blood sample within two weeks of assessment
date. Participants will be referred to local pathology clin-
ics by their primary care doctor and will visit the clinics by
their own arrangement. Blood samples will be analysed
for determination of total cholesterol (TC), low density
lipoprotein cholesterol (LDL-C), high density lipoprotein
cholesterol (HDL-C) and triglycerides (TG). Repeat blood
tests will be carried out at the same pathology clinic wher-
ever possible.
Resting BP will be measured from the brachial artery using
an Omron digital automatic BP (Omron Healthcare Co
Ltd Model M5, Japan). The automatic BP monitor will be
calibrated against a mercury sphygmomanometer prior to
study commencement and has been demonstrated to be
accurate. The Omron M6 is accurate for BP to within 3
mmHg [26] and fulfills the recommendation criteria of
the international protocol when tested against a mercury
sphygmomanometer for diastolic and systolic BP readings
[27]. For measurement, appropriate cuff size will be
selected, each participant will be seated with the right arm
supported and two consecutive blood pressure readings
will be collected with one minute interval according to
previously published guidelines [28].
Smoking status will be initially assessed by analysis of car-
bon monoxide (CO) levels using a hand-held breath ana-
lyzer or CO meter (Bedfont micro smokerlyzer, Scientific
Ltd, England) using new mouthpieces (Airmet Scientific
EC50MP500, Victoria Australia) for each participant, for
infection control purposes. Participants will be expected
to blow into the mouthpiece for the 15 seconds and the
result are to be recorded in parts per million (ppm). The
criteria for recent, within the past 24 hours, smoking will
be an expired CO greater than 5 ppm [29]. Smoking status
will be confirmed with self report to identify participants
who concealed their true smoking status. Participants will
be asked whether they had ever smoked, how long since
they started or stopped and if they smoked, what is/was
the average number of cigarettes smoked per day.
Physical activity levels will be assessed using the Interna-
tional Physical Activity Questionnaire (IPAQ) score [30].
The short, last-seven-days, self-administered format (last
revised August 2002) comprises seven questions that seek
information about the duration and frequency of vigor-
ous and moderate physical activity as well as rest and
walking in the past seven days. The IPAQ was developed
as an international measure of physical activity, for use in
adults, and has been tested for reliability and validity
across 12 countries [31]. For final scoring, responses are
divided into three categories, MET-minutes per week,
average time spent sitting per day and a categorical level of
physical activity. The categorical score is further divided
into three levels – insufficiently active, sufficient activity
and highly active.
For assessment of depressive mood, the Cardiac Depres-
sion Scale (CDS) score will be used [32]. The CDS was
developed from the responses of cardiac outpatients and
comprises 26 items with subscales relating to sleep, uncer-
tainty, mood, cognition, hopelessness and inactivity.
Some items are scored in reverse and raw scores are used
for analysis where higher scores indicate depressed mood
and a score of greater than 90 represents depressive mood.
When assessed for test-retest reliability over two weeks
scores were 64.9 ± 23.3 (mean ± SD) and 63.1 ± 23.0 with
correlation coefficient of 0.86 and score difference of -1.9
± 12.2 (mean ± SD). Permission has been obtained to
administer the CDS from Professor Hare, Department of
Cardiology (Austin & Repatriation Medical Centre, Aus-
tralia).
For assessment of overweight, body mass index (BMI) will
be calculated using the standard equation (BMI = weight
kg/height m2). Each participant's body weight will be
measured when lightly clothed and in bare feet using dig-
ital scales (Tanita EB727, Australia) to the nearest 0.1 kg.
Height will be measured without shoes using a standiom-
eter (Stature Meter 2 m 1013522, Livingston International
Pty Ltd, NSW Australia) to the nearest 0.5 cm and accord-
ing to best anthropometic practice [33].
Health related quality of life (HRQOL) will be assessed
using the SF36 health survey [], [35]. The SF36 comprises
11 items that ask for the participant's views about their
health, how they feel and whether they are able to per-
form certain activities and has been tested for reliability
and validity [], [35]. A license has been obtained to use the
SF36 for data collection from 300 patients on three occa-
sions per participant (License number F1-052203-
13860). SF36 scores will be coded, summed and trans-
formed onto a scale from 0 (worst possible health) to 100
(best possible health) using the method described in the
user manual [36].
Relative cardiac risk will be calculated using the LIPID
score which was developed for use in secondary preven-
tion [37]. An individual's risk score calculation involves
aggregating risk point estimates corresponding to the
patient's risk factor profile. Aggregate scores provide an
indication of the level of risk for a future ACS. The scoresBMC Cardiovascular Disorders 2006, 6:26 http://www.biomedcentral.com/1471-2261/6/26
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are divided as low risk (≤ 4), medium risk (5–6), high risk
(7–9) and very high risk (≥ 10) [37]. Further, each partic-
ipants number of modifiable risk factors will be calculated
using the cut points; TC > 4.0 mmol/L, SBP ≥ 140 mmHg,
current smoking, physical inactivity using the categorical
IPAQ score, BMI ≥ 30 kg/m2, known diabetes and a CDS
score ≥ 90 for depression.
Each participant's knowledge of their own cardiovascular
risk factors will also be assessed at baseline, three and 12
months. Participants will be asked if they can state any of
their own modifiable risk factors for heart disease and the
number stated will be compared to the each individual's
actual number of modifiable risk factors. Participants will
then be asked if they are able to state the Australian rec-
ommended targets for total cholesterol, BP, physical activ-
ity and whether or not smoking is recommended for
people with CHD.
Procedure
Conventional care group
Participants randomly allocated to the conventional care
group will continue to manage their heart health as
directed by their primary care doctor or by their own cog-
nisance. This group will not receive any additional inter-
vention as a result of participation in the study. However,
they will be contacted by telephone 2–3 weeks after base-
line assessment to confirm their three month assessment
appointment. In addition, each participant's general prac-
titioner (GP) and cardiologist will be mailed a courtesy
letter following baseline assessment and a risk factor sum-
mary with recommendations for discussion regarding
long-term risk factor management following the final 12
month assessment.
Modular group
Participants randomly allocated to the modular group
will manage their heart health by participation in modu-
lar guided self-choice management of heart disease. That
is, participants will participate in risk factor modules of
their choice, with the exception of the mandatory blood
cholesterol module, strive to achieve mutually-agreed
goals and make choices about risk factor reduction inter-
ventions based on their own circumstances. Following
baseline assessment, the consultation will be extended by
approximately 30 minutes for selection of modules, goal
setting and shared decision making about risk factor inter-
ventions.
The risk factor modules consist of cholesterol-lowering,
BP management, smoking cessation and physical activity.
All participants will participate in the cholesterol-lower-
ing module and where applicable, participants can also
choose up to two other modules depending on their indi-
vidual risk factor assessment and personal preference.
Therefore, all participants will participate in a minimum
of one risk factor module and a maximum of three mod-
ules at any one time.
The mandatory cholesterol-lowering module involves
pharmacological intervention in consultation with the
primary care doctor as well as education and empower-
ment through information and support about individual
and nationally recommended cholesterol levels. The three
optional modules involve choice of intervention includ-
ing; following medical advice; participating in a structured
program (individual or group); participating in a home
program; or self-help. All risk factor modules will be
resourced and delivered separately among the primary
care doctor, the local area health service, the local commu-
nity and the participant. Participants in the modular
group will receive a resource package including appropri-
ate information leaflets which contain guidelines and
information about the module and contact information
for community heart health programs. The leaflets have
been developed and pilot tested, for validity, by health
professionals and consumers.
For each risk factor module, a three month objective goal
will be set based on shared decision-making. The mutu-
ally-agreed goal will be based on the each participant's
risk factor profile, social factors, commitments and per-
sonal preference. Participants will also asked to rate their
confidence in achieving the set goal on a visual analogue
scale from 1–10. Each risk factor baseline level, mutually
agreed goal, time frame and confidence rating will be
recorded on the information leaflet.
All participants in the modular group will also be
"coached" using a previously published model [38]. The
coaching model is a five stage cyclic process and involves
assessing understanding, providing education, assertive-
ness training and reassessment. In this study, the first
coaching session will be conducted during the initial face-
to-face shared decision making, goal setting session. Par-
ticipants will then be coached over the telephone on up to
four further occasions, depending on goal achievement,
during the following three months depending on need.
Once each risk factor goal is achieved, no further coaching
is required. All coaching will be conducted by a researcher
who has been trained by the original coach study coordi-
nator. During each coaching session individual's knowl-
edge of their risk factors and personal goals will be
identified and participation in the module will be estab-
lished and recorded.
Communication between the study coordinator, the par-
ticipant and health professionals involved and commu-
nity services will be facilitated where possible. Each
participant will also be encouraged to communicateBMC Cardiovascular Disorders 2006, 6:26 http://www.biomedcentral.com/1471-2261/6/26
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openly about their goals and modules with their local
doctor and cardiologist. During the course of the study,
participants identified as being clinically depressed,
according to their CDS, are to be offered an appointment
with a clinical psychologist specialising in heart disease.
For each participant, their GP and cardiologist will be sent
a comprehensive letter outlining the participant's risk fac-
tors, goals and chosen modules. Following the final 12
month assessment, all participants and their doctors will
also receive a cardiac risk factor summary and recommen-
dations for discussion regarding long term risk factor
management. By facilitating communication, it is antici-
pated that each participant receives a coordinated multi-
disciplinary approach to their own risk factor
management based on need and situation.
Standard rehabilitation group
Participants who volunteer for the standard rehabilitation
group will attend the hospital-based outpatient cardiac
rehabilitation program. This rehabilitation program
includes twice weekly group hospital-based exercise
classes for six weeks and weekly education sessions. The
exercise program is supervised by a clinical nurse special-
ist and a physiotherapist. The exercise sessions are gener-
ally of 45 minutes duration and include a 10 minute
warm up and cool down and approximately 30 minutes
of cardiovascular and resistance exercise stations. These
stations include leg press, treadmill walking, stair climb-
ing, knee extension weights, stationary cycling and gentle
upper limb weights. Each station is conducted for 3 min-
utes and patients rotate around the room from station to
station with a 2 minute rest between stations. Exercise
intensity is based on rating of perceived exertion (RPE) at
a moderate level (3–4) on the modified RPE scale [39].
The education sessions, include general information
about heart disease and associated risk factors, two ses-
sions by a pharmacist about medications, two sessions
about dietary advice by dietitian (one theoretical and one
practical session), two sessions from a clinical psycholo-
gist and one session about exercise by a physiotherapist.
Participants will be encouraged to attend two exercise ses-
sions per week and all the educational sessions if possible.
There is no transport available for travel to and from the
sessions however, parking is available in the hospital car-
park at each patient's expense. Similar to the conventional
care group, the standard rehabilitation group will not
receive any additional intervention as a result of participa-
tion in the study. However, all participants will be con-
tacted by telephone 2–3 weeks after baseline assessment
to confirm their three month appointment. In addition,
each participant's GP and cardiologist will be mailed a
courtesy letter following baseline assessment and a risk
factor summary with recommendations for discussion
regarding long term risk factor management following the
final 12 month assessment.
Sample size
Participant numbers required for each group have been
calculated to detect a 0.5 mmol/L reduction in TC with
80% power. The LIPID study of 9014 subjects with CHD
reported a mean TC of 5.6 (± 0.7) mmol/L [40] and it has
been assumed that a clinically significant change in TC
would be 0.5 mmol/L. Therefore, to achieve power of
80% to detect a change of 0.5 of a SD unit, using a two-
tailed test with an alpha level of 0.05 and allow for 10%
loss to follow-up, it was calculated that 72 participants per
group will be recruited.
Data analysis
Data will be analysed by intention-to-treat using SPSS for
Windows (Version 12.01) and will be presented as mean
and standard error of the mean or proportions. Differ-
ences in outcome measures, between and within groups,
will be compared using repeated measures ANOVAs for
continuous variables and either χ2 tests or Fishers exact
tests, as appropriate, for proportions of categorical varia-
bles. Two tailed p values of < 0.05 will be considered sig-
nificant.
Discussion
The majority of patients with CHD do not access existing
cardiac rehabilitation programs. Testing of alternative
models of secondary prevention will potentially provide
beneficial programs for more high risk patients following
ACS.
We have presented the rationale and design for a ran-
domised controlled trial testing a modular approach to
the secondary prevention of CHD. The study is also
designed to compare outcomes to benchmarks set by
patients participating in standard cardiac rehabilitation.
The primary outcomes will be the magnitude of CHD
modifiable risk factors and secondary outcomes will be
relative CHD risk and knowledge of these factors.
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